NCT05095441View on ClinicalTrials.gov

A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2026

Conditions
Solid TumorGlioblastomaGlioblastoma MultiformeGlioblastoma Multiforme of Brain
Interventions
BIOLOGICAL

C5252

A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

ImmVira Pharma Co. Ltd

INDUSTRY

NCT05095441 - A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | Biotech Hunter | Biotech Hunter